ENPICOM Enters Into Service Agreement with Neogene Therapeutics

Pharma Tech Outlook: Pharma Tech Magazine

ENPICOM Enters Into Service Agreement with Neogene Therapeutics

By Pharma Tech Outlook | Wednesday, November 18, 2020

Jos Lunenberg, CEO

ENPICOM is extremely proud to add Neogene Therapeutics to its IGX Platform customer base.

FREMONT, CA: ENPICOM, an innovative bioinformatics software engineering firm delivering ground-breaking products and customized solutions to decode the immune system and enhance human health, announces the company has entered into a service agreement with Neogene Therapeutics to give the company access to ENPICOMs cloud-based IGX Platform to manage, organize, and analyze T cell sequencing data. ENPICOM has also developed several customizations to make sure that the platform's functionality fits Neogene's data handling workflow to help Neogenes research team use the full potential of their immune repertoire data. Neogene's recent $100 million Series A shows how essentia this new type of immunotherapy has become in the last few years.

Dedicated to creating personalized neoantigen T cell receptor (TCR) therapies for cancer, Neogene Therapeutics studies cancer patients' immune repertoires by high-throughput T cell sequencing to find T cell receptor genes with therapeutic value. Personalized neo-antigen TCR therapy is a new approach to cancer treatment. Patients T cells are genetically engineered with neoantigen-specific TCR genes to enable them to identify and destroy tumor cells.

ENPICOM and the Neogene team have been partnering for years on several projects. ENPICOM has always been a thoughtful and reliable partner. It is a pleasure to use ENPICOM's innovative and IGX Platform. Since immune repertoire sequencing indicates the generation of large amounts of data, there is a demand for specific expertise to efficiently manage and fully exploit the potential of the data collected. ENPICOMs IGX Platform offers Neogene a solution to manage and annotate T cell sequencing data.

The IGX Platform comes with sound data management features and a unique user interface out of the box. Its modular, flexible structure enables for further enhancements and customizations. The custom robust workflow of the IGX Platform positions it to help high-throughput studies needed to power Neogene's research in personalized T cell therapies.

Weekly Brief

Read Also